Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib + Sapacitabine for Breast Cancer
Recruiting1 awardPhase 1
Cambridge, Massachusetts
This trial is attempting to find a more effective treatment for breast cancer, specifically for those with a BRCA mutation. The study will be testing a combination of two drugs, sapacitabine and olaparib, to see if they are more effective than either drug used alone.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.